Galvin Gaustad & Stein LLC Raises Stock Holdings in Zoetis Inc. $ZTS

Key Points

• Galvin Gaustad & Stein LLC increased its holdings in Zoetis Inc. by 6.0%, now owning 68,718 shares valued at $10.7 million.
• A number of large investors, including Vanguard Group and Polen Capital Management, have also boosted their stakes in Zoetis, which is currently 92.80% owned by institutional investors.
• Several analysts have downgraded Zoetis' stock rating, with price targets reduced to between $155 and $165, while others maintain a "Moderate Buy" rating with an average price target of $200.88.

Galvin Gaustad & Stein LLC raised its position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 6.0% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 68,718 shares of the company's stock after purchasing an additional 3,872 shares during the quarter. Galvin Gaustad & Stein LLC's holdings in Zoetis were worth $10,717,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. Vanguard Group Inc. grew its stake in shares of Zoetis by 0.5% during the 1st quarter. Vanguard Group Inc. now owns 41,556,164 shares of the company's stock valued at $6,842,222,000 after purchasing an additional 189,287 shares during the period. Polen Capital Management LLC grew its stake in shares of Zoetis by 17.6% during the 1st quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company's stock valued at $1,448,401,000 after purchasing an additional 1,313,653 shares during the period. Northern Trust Corp grew its stake in shares of Zoetis by 1.2% during the 1st quarter. Northern Trust Corp now owns 6,504,902 shares of the company's stock valued at $1,071,032,000 after purchasing an additional 78,508 shares during the period. Goldman Sachs Group Inc. grew its stake in shares of Zoetis by 2.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 5,146,024 shares of the company's stock valued at $847,293,000 after purchasing an additional 109,791 shares during the period. Finally, Brown Advisory Inc. grew its stake in shares of Zoetis by 7.6% during the 1st quarter. Brown Advisory Inc. now owns 4,408,542 shares of the company's stock valued at $725,866,000 after purchasing an additional 312,746 shares during the period. 92.80% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on ZTS shares. Leerink Partners downgraded Zoetis from an "outperform" rating to a "market perform" rating and cut their price target for the company from $180.00 to $155.00 in a research note on Thursday, July 17th. Stifel Nicolaus downgraded Zoetis from a "buy" rating to a "hold" rating and cut their price objective for the company from $165.00 to $160.00 in a research note on Wednesday, June 18th. Leerink Partnrs downgraded Zoetis from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 17th. Weiss Ratings reiterated a "hold (c-)" rating on shares of Zoetis in a research note on Wednesday. Finally, Argus reiterated a "buy" rating and set a $190.00 price objective on shares of Zoetis in a research note on Tuesday, September 9th. Five investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company's stock. According to MarketBeat, Zoetis presently has an average rating of "Moderate Buy" and an average price target of $200.88.

Zoetis Stock Down 0.1%

NYSE ZTS opened at $143.32 on Friday. The stock's 50 day moving average is $149.36 and its 200 day moving average is $154.60. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05. Zoetis Inc. has a 12 month low of $139.34 and a 12 month high of $196.55. The stock has a market cap of $63.52 billion, a PE ratio of 24.67, a P/E/G ratio of 2.30 and a beta of 0.90.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, topping analysts' consensus estimates of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The company had revenue of $2.46 billion for the quarter, compared to analysts' expectations of $2.41 billion. During the same period in the previous year, the firm earned $1.56 EPS. The firm's revenue was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Research analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st will be issued a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a dividend yield of 1.4%. The ex-dividend date of this dividend is Friday, October 31st. Zoetis's dividend payout ratio is 34.42%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.